Esophageal Adenocarcinoma Methods and Protocols

(sharon) #1
211


  1. Zhou Z, Xia Y, Bandla S, Zakharov V, Wu S,
    Peters J, Godfrey TE, Sun J (2014) Vitamin D
    receptor is highly expressed in precancerous
    lesions and esophageal adenocarcinoma with
    significant sex difference. Human Pathol
    45:1744–1751. https://doi.org/10.1016/j.
    humpath.2014.02.029

  2. Boonstra JJ, van Marion R, Douben HJ,
    Lanchbury JS, Timms KM, Abkevich V, Tilanus
    HW, de Klein A, Dinjens WN (2012) Mapping
    of homozygous deletions in verified esophageal
    adenocarcinoma cell lines and xenografts.
    Genes Chromosomes Cancer 51:272–282.
    https://doi.org/10.1002/gcc.20952

  3. Soutto M, Peng D, Razvi M, Ruemmele P,
    Hartmann A, Roessner A, Schneider-Stock R,
    El-Rifai W (2010) Epigenetic and genetic
    silencing of CHFR in esophageal adenocarci-
    nomas. Cancer 116:4033–4042. https://doi.
    org/10.1002/cncr.25151

  4. Bandla S, Peters JH, Ruff D, Chen SM, Li CY,
    Song K, Thoms K, Litle VR, Watson T,
    Chapurin N, Lada M, Pennathur A, Luketich
    JD, Peterson D, Dulak A, Lin L, Bass A, Beer
    DG, Godfrey TE, Zhou Z (2014) Comparison
    of cancer-associated genetic abnormalities in
    columnar-lined esophagus tissues with and
    without goblet cells. Ann Surg 260:72–80.
    https://doi.org/10.1097/
    SLA.0000000000000424

  5. Zhang K, Wu X, Wang J, Lopez J, Zhou W,
    Yang L, Wang SE, Raz DJ, Kim JY (2016)
    Circulating miRNA profile in esophageal ade-
    nocarcinoma. Am J Cancer Res 6:2713–2721

  6. Goh XY, Rees JR, Paterson AL, Chin SF,
    Marioni JC, Save V, O’Donovan M, Eijk PP,
    Alderson D, Ylstra B, Caldas C, Fitzgerald RC
    (2011) Integrative analysis of array-compara-
    tive genomic hybridisation and matched gene
    expression profiling data reveals novel genes
    with prognostic significance in esophageal ade-
    nocarcinoma. Gut 60:1317–1326. https://
    doi.org/10.1136/gut.2010.234179

  7. Silvers AL, Lin L, Bass AJ, Chen G, Wang Z,
    Thomas DG, Lin J, Giordano TJ, Orringer
    MB, Beer DG, Chang AC (2010) Decreased
    selenium-binding protein 1 in esophageal ade-
    nocarcinoma results from posttranscriptional
    and epigenetic regulation and affects chemo-
    sensitivity. Clin Cancer Res 16:2009–2021.
    https://doi.org/10.1158/1078-0432.
    ccr-09-2801

  8. Obulkasim A, Ylstra B, van Essen HF, Benner
    C, Stenning S, Langley R, Allum W,
    Cunningham D, Inam I, Hewitt LC, West NP,
    Meijer GA, van de Wiel MA, Grabsch HI
    (2016) Reduced genomic tumor heterogeneity
    after neoadjuvant chemotherapy is related to


favorable outcome in patients with esophageal
adenocarcinoma. Oncotarget 7:44084–44095.
https://doi.org/10.18632/oncotarget.9857


  1. Aichler M, Motschmann M, Jutting U, Luber
    B, Becker K, Ott K, Lordick F, Langer R, Feith
    M, Siewert JR, Walch A (2014) Epidermal
    growth factor receptor (EGFR) is an indepen-
    dent adverse prognostic factor in esophageal
    adenocarcinoma patients treated with cisplatin-
    based neoadjuvant chemotherapy. Oncotarget
    5:6620–6632. https://doi.org/10.18632/
    oncotarget.2268

  2. Xu E, Sun W, Gu J, Chow WH, Ajani JA, Wu X
    (2013) Association of mitochondrial DNA
    copy number in peripheral blood leukocytes
    with risk of esophageal adenocarcinoma.
    Carcinogenesis 34:2521–2524. https://doi.
    org/10.1093/carcin/bgt230

  3. Lee S, Han MJ, Lee KS, Back SC, Hwang D,
    Kim HY, Shin JH, Suh SP, Ryang DW, Kim
    HR, Shin MG (2012) Frequent occurrence of
    mitochondrial DNA mutations in Barrett’s
    metaplasia without the presence of dysplasia.
    PLoS One 7:e37571. https://doi.
    org/10.1371/journal.pone.0037571

  4. Geppert CI, Rummele P, Sarbia M, Langer R,
    Feith M, Morrison L, Pestova E, Schneider-
    Stock R, Hartmann A, Rau TT (2014) Multi-
    colour FISH in esophageal
    adenocarcinoma-predictors of prognosis inde-
    pendent of stage and grade. Br J Cancer
    110:2985–2995. https://doi.org/10.1038/
    bjc.2014.238

  5. Ismail A, Bandla S, Reveiller M, Toia L, Zhou
    Z, Gooding WE, Kalatskaya I, Stein L, D’Souza
    M, Litle VR, Peters JH, Pennathur A, Luketich
    JD, Godfrey TE (2011) Early G(1) cyclin-
    dependent kinases as prognostic markers and
    potential therapeutic targets in esophageal ade-
    nocarcinoma. Clin Cancer Res 17:4513–4522.
    https://doi.org/10.1158/1078-0432.
    ccr-11-0244

  6. Bang YJ, Van Cutsem E, Feyereislova A,
    Chung HC, Shen L, Sawaki A, Lordick F,
    Ohtsu A, Omuro Y, Satoh T, Aprile G,
    Kulikov E, Hill J, Lehle M, Ruschoff J, Kang
    YK, To GATI (2010) Trastuzumab in combi-
    nation with chemotherapy versus chemother-
    apy alone for treatment of HER2-positive
    advanced gastric or gastro-esophageal junc-
    tion cancer (ToGA): a phase 3, open-label,
    randomised controlled trial. Lancet 376:687–
    697. https://doi.org/10.1016/
    S0140-6736(10)61121-X

  7. Almhanna K, Meredith KL, Hoffe SE, Shridhar
    R, Coppola D (2013) Targeting the human
    epidermal growth factor receptor 2 in esopha-
    geal cancer. Cancer Control 20:111–116


DNA Copy-Number in Esophageal Adenocarcinoma
Free download pdf